periods of only six weeks, and the difficulties of determining equivalent dosages for the two active drugs being compared (Rey et a!, 1989) . With regard to the latter problem, differences in sedation or the induction of parkinsonism between the drug treatments could confound the assessment of negative symptoms in the treatment groups, and differences in antipsychotic potency might be relevant in terms of the response of secondary negative symptoms (Barnes, 1994) . This study was designed to overcome these methodological issues by attempting to reduce each patient's dosage towards the minimum effective dose, allowing the two treatment groups to be compared on the basis of clinically-equivalent regimes. The main aim of the study was to examine the claims for a specific beneficial effect for low-dose substituted benzamides on negative syrnp toms in chronic schizophrenia. A further aim was to assess the impact of progressive reduction of antipsychotic drug dose on negative symptoms.
METHOD Patients
DSMâ€"IIIâ€"R criteria for schizophrenia (American Psychiatric Association, 1987) were applied to all in-patients on 18 con tinuing care and rehabilitation wards at two psychiatric hospitals. Eligible patients were those with moderate to severe negative symptoms, achieving a combined score of 4 or more on the flatness of affect and poverty of speech items (negative sub-scale) of the Manchester Scale (MS; Krawiecka et a!, 1977) . Patients were excluded if they were taking other psychotropic medication or receiving an antipsychotic drug dose equivalent to 1200 mg a day or more of chlorpromazine (see Table 1 ) because the dramatic dose reduction necessary to reach the low dose may have produced an unacceptably high rate of psychotic relapse.
Design
This was a one-year, double-blind, com parative study of amisulpride and haloper idol, using a double-dummy design. No other antipsychotic medication was allowed.
Patients were randomly allocated to either amisulpride or haloperidol at one of six dose levels calculated to be the closest equivalent to their previous antipsychotic medication. The six dose levels used were 800 mg, 600 mg, 450 mg, 300 mg, iSO mg and 100 mg a day of amisuipride, and the , 1997) . Such confounds are more likely to be present in treatment studies of acute psychotic episodes, and a key clinical issue is the extent to which drug efficacy for negative symptoms in such a setting can be extrapolated to the treatment of persistent deficit symptoms in patients during a more stable phase of illness.
According to animal studies (Puech et a!, 1984) , substituted benzamide drugs possess novel properties at low doses, when they are reputed to stimulate rather than suppress dopaminergic systems, an effect postulated to be mediated by presynaptic receptors. Ami sulpride was chosen for this study as a more potent substituted benzamide than sulpiride, due to its higher affinity for dopamine D2 and D3 receptors and its greater lipid solubility. In previous double-blind studies, amisulpride has shown an antipsychotic effect not sig nificantly different from, or marginally better than that of haloperidol and flupenthixol (Delcker et a!, 1990; Hillert et a!, 1994) , and these studies also indicated that amisulpride is well tolerated. Placebo-controlled studies have also suggested efficacy in the treatment of negative symptoms, particularly in low dosage (Boyer et a!, 1995; Paillere-Martinot et a!, 1995; Loo et a!, 1997) .
Methodological problems in comparative studies in this area include short treatment
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One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms approximate equivalents for haloperidol, which were 20 mg, 16 mg, 11.5 mg, 8 mg, 4.5 mg and 3 mg a day respectively. Seven patients who were not receiving antipsycho tic medication before entering the study started on the lowest dose level. For patients receiving depot medication there was a three-month washout period before entering the study, during which they received an equivalent oral dose of haloperidol. Procyc lidine was the only anticholinergic agent allowed during the study. Patients already receiving regular anticholinergic medication before the study were switched to an equivalent dose of procyclidine.
Every three months during the study, each patient's trial medication was reduced to the next lowest level, unless the lowest study dose level had been reached or there was evidence of a psychotic exacerbation, defined as an increase of three or more on the combined score for the thought distur bance and paranoia items of the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962; Marder et a!, 1984) . Such exacerbations were treated with successive dose level increases prescribed until there was a satisfactory clinical response, up to a maximum dose equivalent of 1SOOmg of chlorpromazine a day. If the psychotic exacerbation could not be controlled within these constraints, the patient was considered to have suffered a psychotic relapse and withdrawn from the study. Also, every three months, the need for continuing procyc lidine was reviewed on the basis of an examination for parkinsonism, with the aim of minimising the use of this drug.
For each patient, basic demographic data were collected on age, gender, length of illness and total duration of hospitalis ation. Mental state and adverse effects were assessed before entering the study, at 6 and 12 weeks and then at 6, 9 and 12 months. The scales used to rate positive and negative symptoms, depression and other mental state phenomena were the MS. BPRS, the Scale for the Assessment of Negative Symp toms (SANS; Andreasen, 1989 ) and the Comprehensive Psychopathological Rating Scale (CPRS; Asberg et a!, 1978) . Drug induced movement disorder was assessed, on the same occasions as mental state, using the Extrapyramidal Rating Scale (EPRS; Simpson & Angus, 1970) , the Barnes Akathisia Rating Scale (BARS; Barnes, 1989) and the Tardive Dyskinesia Scale (TDS; Barnes & Trauer, 1982) . Social behaviour was assessed by two raters (D.C., C.P.) at baseline and at 12 months using the Social Behaviour Schedule (SBS; Wykes & Sturt, 1986) . The SBS ratings were carried out independently of the patient interviews, being based largely on infor mation from the nursing staff. The rater conducting the main assessment interviews (J.S.) received a series of training sessions with both videotaped and live patient inter views and examinations to improve the reliability of the ratings. A checklist of potential antipsychotic side-effects was com pleted at each three-month review.
Statistical analysis
The statistical analysis compared the â€˜¿ end point' or â€˜¿ last value' ratings for selected items using a pragmatic approach on pa tients who provided data at the first three month visit at least. These 54 patients (28 receiving amisulpride, 26 receiving haloper idol) were defined as the efficacy popu lation. Two-sided statistical tests were conducted at the 5% level of significance. No formal account was made of multiple testing, but specific primary and secondary end-points were identified prior to analysis. The treatment groups were compared using the two-sample f-test on the mean change from baseline for each selected end-point. The equivalent non-parametric method, the Wilcoxon rank sum test, was used on those occasions where the assumptions for the t test were violated. x2 was used for compar ison of proportions. Significance tests corn paring the groups at baseline were not No clinicaldiagnosisofsenile dementia
Not due for imminent discharge ii om hospital undertaken as this is not deemed generally to be of value (Altman, 1991) .
RESU LTS
Sixty patients were recruited into the study (Table 1) . Table 2 provides details of the baseline characteristics of the total sample and the amisulpride and haloperidol treat ment groups. During the study 12 patients were withdrawn, six within the first three months (one receiving amisulpride and five haloperidol). Four individuals were related to intercurrent physical illness (three ami sulpride, one haloperidol), four were due to extrapyramidal symptoms (haloperidol), two were due to non-compliance (one in each treatment group), one patient with drew consent (amisulpride) and one patient (haloperidol) was withdrawn because of a psychotic relapse. Of the 54 patients re rnaining in the study longer than three months (the efficacy population), five (18%) in the amisulpride group and nine (35%) in the haloperidol group experienced psychotic exacerbations which were con trolled with increase in dosage, but this difference was not statistically significant.
By one year, 22 (76%) of the patients started on amisulpride had achieved or maintained a low dose level of 150 mg or 100 mg a day, and 18 (58%) of those started on haloperidol were similarly re ceiving the estimated equivalent low dose of 4.5 mg or 3 mg a day. In the arnisul pride group, 11 (38%) patients had at least 
Table2 Characteristics ofthetreatment groups andtotalsample Negative symptoms
Negative symptoms were essentially un changed over the study period in the total sample. Nevertheless, comparing the two treatment groups, the amisulpride patients showed a greater reduction for the affective flattening and the avolitionâ€"apathy global items of the SANS at a trend level of significance (see Table 3 ). At baseline, there were no significant correlations between ratings for MS items for flattened affect and poverty of speech and ratings on the MS depression item or the EPRS global score. In advance of the study, a reduction of two or more on the MS negative symptom sub-scale score had been considered as a clinically significant change. Eleven patients (six in the amisulpride group, five receiving haloperidol) fulfilled this criterion, but showed no consistent parallel reductions in scores on the MS positive symptom sub-scale, the MS depres sion item or the global EPRS item score.
Positive symptoms
The mean score of the MS positive symptom sub-scale at baseline was 3.00 (s.d. 3.4) and 3.07 (s.d.3.4) by the endof the studyperiod, which is an indication that despite the dose reduction strategy, positive symptoms were stable over the year for those patients remaining in the study. Similarly, social behaviour ratings showed no significant changes over the year in the sample or between the treatment groups. The mean Behaviour Severe score of the SBS at baseline for all patients entering the study was 2.89, and the mean score at the end of the study was
Comparison of the groups revealed no significant difference (t-test, P=O.90).

Side-effects
The side-effects recorded were mainly anti cholinergic, and there was a tendency for amisulpride patients to experience fewer of these (see Table 4 ). No single side-effect stands out with regard to treatment differ ences. At the start of the study, there was no significant difference between the two treat ment groups in terms of the proportion receiving anticholinergic medication (38.S% in the haloperidol group, 41% in the arnisulpride group). However, by the end of the trial, only nine (32%) of the 28 amisulpride patients were still receiving procyclidine compared with 20 (77%) of the 26 patients in the haloperidol group, a difference which was statistically significant I. Chlorpromazine equivalents. mg/day (Rey et al, I989) .
Thble 3 Baselineandchangein negativesymptom scoresmeasuredon the ManchesterScale(MS) Scalefor the
Assessment of Negative Symptoms (SANS) and Brief Psychiatric Rating Scale (BPRS) in the two treatment groups overoneyear one dose reduction while the respective figure for the haloperidol patients was six (19%). However, as a result of dosage increases to tackle psychotic exacerbations, five arnisulpride patients (18%) and seven haloperidol patients (27%) were receiving higher doses of medication after one year than at baseline. Table4 Adverse effects experienced atleast once duringthe study negative symptoms in schizophrenia, metho dological recommendations include the selec tion ofpatients characterised by predominant negative symptoms and only modest scores for positive psychotic symptoms (MÃ ¶lleret a!, 1994) . However, as the recruitment process for this study revealed, such patients tend to be in a minority. While the selection of a patient sample with marked and persistent negative symptoms allowed the efficacy of the low-dose regimens on such symptoms to be evaluated, the findings should only be generalised with caution to the majority of patients with schizophrenia.
Negative symptoms
The low-dose regimes with amisulpride and haloperidol tested in this study failed to produce any significant reduction in mean scores for the negative symptoms. How ever, comparing the two treatments, there was a trend for greater improvement in affective flattening and avolitionâ€"apathy sub-scale scores in the amisulpride group. This relative lack of response may be related to the severe and enduring nature of these features in this sample of ageing, long-stay in-patients. Thus, any particular benefit for low-dose amisulpride in improv ing negative symptoms was not confirmed in this sample.
A subgroup of 11 patients from the total sample showed a reduction in negative symptoms to a criterion level that had been judged, a priori, to be of clinical significance. This change may have been a response either to the dose reduction strategy or to the increased attention and clinical scrutiny associated with participation in a clinical trial. Since there was no association between this improvement and change in positive symptoms, parkinsonism or depressive symp toms, the reduction in negative symptom sub scale score could not be explained by the successful treatment of these other symptoms, that is, an improvement in secondary negative symptoms. Nevertheless, these data are not, in themselves, sufficient to establish that the change was in primary negative symptoms (Carpenter et a!, 1995) .
Positive symptoms
Over the study period, this sample of in patients with chronic schizophrenia charac tensed by negative symptoms showed no overall change in positive symptom scores. This was despite psychotic exacerbations requiring an increase in dose occurring in nearly a fifth of the patients receiving amisulpride and over a third of those on haloperidol. However, one year may be too short a period to assess the increased risk of relapse from using low doses (Marder et a!, 1987) .
The psychotic exacerbations responded so well to prompt increase of medication that only one patient had to be withdrawn because of deterioration of mental state. This suggests that the consequences of psychotic exacerbations on low-dose treat ment may not be as serious as those occurring after complete drug withdrawal (Kane et a!, 1983) , even in severely and chronically ill hospitalised patients with schizophrenia. However, the hospital envir onment allowed a greater degree of mon itoring and support than would be possible with out-patients.
Side-effects
Tardive dyskinesia was present in the majority of patients at the start of the study and did not change significantly in the sample as a whole or between treatment groups, despite the dose reduction strategy, which might have been expected to provoke exacerbation of the condition.
Differences in parkinsonian side-effects favouring amisulpride were not significant, although the greater use of anticholinergic medication in the haloperidol group would have tended to minimise differences in parkinsonism, as throughout the study parkinsonism was regularly assessed and treated, and anticholinergic medication was tailed off when it was absent. The signifi cantly smaller proportion of patients in the amisulpride group requiring this medication suggests a relatively lower liability for parkinsonism side-effects with this drug. Anticholinergic side-effects were more fre quently reported by patients on haloperidol, and the prescription of anticholinergic drugs can have serious consequences which in dude misuse for their euphoriant properties, and a range of side-effects of their own (Barnes & McPhillips, 1996) .
Conclusion
The risks and benefits of strategies for dose reduction have been examined in a series of studies (Schooler, 1991 ) . In this selected sample of severely disabled in-patients with chronic schizophrenia characterised by pre dominant negative symptoms, their deficit state, as measured by both symptoms and social behaviour, showed little change over the one-year study period despite the dose tion of the study, parkinsonian side-effects were rated as definitely present in 15 (54%) of the amisulpride patients and 19 (73%) of the haloperidol patients, and, on the basis of the diagnostic threshold score on the BARS global sub-scale, the figures for akathisia were one patient on amisulpride and three on haloperidol, but none of these differences were statistically significant. Within the efficacy population, tardive dyskinesia ratings showed only minimal change over one year, and did not differ significantly between treatment groups at either the beginning or end ofthe study. Using a criterion threshold score of 2 or more on the orofacial dyskinesia sub-scale of the TDS, 25 (89%) of the amisulpride group exhibited orofacial dyskinesia at the start of the study compared with 22 (85%) patients within the haloperidol group, making possible the cx amination of the effect of this treatment strategy on pre-existing tardive dyskinesia, but leaving little scope for new-onset cases to develop. By the end of the study, the respective figures were 26 (93%) and 25 (96%).
DISCUSSION
Selection of patients with predominant negative symptoms
For clinical trials of drug treatment seeking to test whether there is a therapeutic effect on reduction strategy adopted. The findings suggest that in such patients, negative symptoms are relatively stable phenomena that can be assessed by the scales currently available as discrete clinical entities which are largely independent of positive symp toms, depressive features or dose-related effects, including parkinsonism. . The strategyof titration to low-doseof antipsychoticmedicationwas practicablein this sample of in-patients, as close monitoring and a rapid response to psychotic exacerbations was possible. It would be more difficult to maintain the same level of . One year maybe too short a time to evaluateanyincreasedriskof relapse
